Clinical · Molecular biology
Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption
Summary
This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.
Critical appraisal
Clinical. This discovery holds significant clinical promise, offering an approach to target RAS-driven cancers irrespective of specific RAS mutational status (KRAS, NRAS, HRAS) and even in wild-type RAS cases. This represents a substantial advancement compared to subtype-specific inhibitors like those for KRASG12C. Furthermore, the ability of these molecules to overcome acquired resistance to BRAF inhibitors in BRAFV600E melanoma is critical, providing a new strategy for patients with treatment failure. Although currently in preclinical stages, these findings warrant Phase I/II clinical trials to assess safety and efficacy in humans, with potential clinical impact projected for 5+ years.
Molecular biology. The research identified a novel class of small molecules that act by covalently binding to an allosteric site within the RAS-binding domain of RAF. This binding induces a conformational change that disrupts the RAS/RAF interaction, thereby blocking downstream signaling. This distinct mechanism of action offers an innovative approach for targeting the RAS/RAF pathway, potentially applicable to a broad spectrum of cancers. Structural studies were crucial in elucidating this mechanism. These molecules could serve as a foundation for developing clinical tests to identify patients likely to benefit from this therapy, particularly those with diverse RAS mutations or resistance to BRAF inhibitors.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology